Bradley Foster & Sargent’s Adaptive Biotechnologies ADPT Stock Holding History

Bradley Foster & Sargent’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-62,126	Closed	-$2.11M	–	447
2021 Q3	$2.11M	Buy	62,126 +786	+1%	+$28.4K	0.05%	182
2021 Q2	$2.51M	Sell	61,340 -54	-0.1%	-$2.1K	0.06%	167
2021 Q1	$2.47M	Buy	61,394 +39,565	+181%	+$2.14M	0.06%	166
2020 Q4	$1.29M	Buy	21,829 +4,651	+27%	+$240K	0.03%	204
2020 Q3	$835K	Buy	+17,178	New	+$722K	0.02%	216

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bradley Foster & Sargent's ADPT Position: Q4 2021 in Review

Bradley Foster & Sargent sold out of Adaptive Biotechnologies (ADPT) in Q4 2021, closing a stake of 62,126 shares — an estimated $2.11M sold.

Bradley Foster & Sargent first reported a position in ADPT in Q3 2020 and held it in 5 quarters. The position peaked at $2.51M in Q2 2021. 214 funds tracked by Wall St. Rank hold ADPT as of Q4 2021.

Bradley Foster & Sargent reported no remaining Adaptive Biotechnologies position as of Q4 2021 after selling out during the quarter.
Bradley Foster & Sargent sold 62,126 Adaptive Biotechnologies shares in Q4 2021, an estimated $2.11M.
Bradley Foster & Sargent first reported a position in Adaptive Biotechnologies in Q3 2020 and held it in 5 quarters.
Bradley Foster & Sargent's Adaptive Biotechnologies position peaked at $2.51M in Q2 2021.
214 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2021.

Based on Bradley Foster & Sargent's 13F filing for Q4 2021, filed 11 Mar 2022.